Millan Mark J
Centre for Therapeutic Innovation in Neuropsychiatry, institut de recherche Servier, 125 chemin de ronde, 78290 Croissy sur Seine, France.
Prog Neurobiol. 2017 Sep;156:1-68. doi: 10.1016/j.pneurobio.2017.03.004. Epub 2017 Mar 18.
The human genome encodes a vast repertoire of protein non-coding RNAs (ncRNA), some specific to the brain. MicroRNAs, which interfere with the translation of target mRNAs, are of particular interest since their deregulation has been implicated in neurodegenerative disorders like Alzheimer's disease (AD). However, it remains challenging to link the complex body of observations on miRNAs and AD into a coherent framework. Using extensive graphical support, this article discusses how a diverse panoply of miRNAs convergently and divergently impact (and are impacted by) core pathophysiological processes underlying AD: neuroinflammation and oxidative stress; aberrant generation of β-amyloid-42 (Aβ42); anomalies in the production, cleavage and post-translational marking of Tau; impaired clearance of Aβ42 and Tau; perturbation of axonal organisation; disruption of synaptic plasticity; endoplasmic reticulum stress and the unfolded protein response; mitochondrial dysfunction; aberrant induction of cell cycle re-entry; and apoptotic loss of neurons. Intriguingly, some classes of miRNA provoke these cellular anomalies, whereas others act in a counter-regulatory, protective mode. Moreover, changes in levels of certain species of miRNA are a consequence of the above-mentioned anomalies. In addition to miRNAs, circular RNAs, piRNAs, long non-coding RNAs and other types of ncRNA are being increasingly implicated in AD. Overall, a complex mesh of deregulated and multi-tasking ncRNAs reciprocally interacts with core pathophysiological mechanisms underlying AD. Alterations in ncRNAs can be detected in CSF and the circulation as well as the brain and are showing promise as biomarkers, with the ultimate goal clinical exploitation as targets for novel modes of symptomatic and course-altering therapy.
人类基因组编码了大量的蛋白质非编码RNA(ncRNA),其中一些是大脑特有的。微小RNA(MicroRNA)能够干扰靶mRNA的翻译,因其失调与阿尔茨海默病(AD)等神经退行性疾病有关,故而备受关注。然而,将关于微小RNA与AD的复杂观察结果整合到一个连贯的框架中仍然具有挑战性。本文借助大量的图表支持,探讨了各种各样的微小RNA如何以趋同和不同的方式影响(并受其影响)AD潜在的核心病理生理过程:神经炎症和氧化应激;β-淀粉样蛋白42(Aβ42)的异常生成;Tau蛋白的产生、切割和翻译后修饰异常;Aβ42和Tau蛋白清除受损;轴突组织紊乱;突触可塑性破坏;内质网应激和未折叠蛋白反应;线粒体功能障碍;细胞周期重新进入的异常诱导;以及神经元的凋亡性丧失。有趣的是,某些种类的微小RNA会引发这些细胞异常,而其他一些则以反调节、保护模式发挥作用。此外,某些微小RNA种类水平的变化是上述异常的结果。除了微小RNA,环状RNA、piRNA、长链非编码RNA以及其他类型的ncRNA也越来越多地与AD相关。总体而言,失调且多功能的ncRNA构成的复杂网络与AD潜在的核心病理生理机制相互作用。ncRNA的改变可以在脑脊液、血液循环以及大脑中检测到,并且作为生物标志物显示出了前景,最终目标是在临床上将其开发为新型对症和改变病程治疗模式的靶点。